Tandem Diabetes Care (TNDM) Current Deferred Revenue (2016 - 2025)
Tandem Diabetes Care (TNDM) has disclosed Current Deferred Revenue for 13 consecutive years, with $9.8 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Current Deferred Revenue fell 76.87% year-over-year to $9.8 million, compared with a TTM value of $9.8 million through Sep 2025, down 76.87%, and an annual FY2024 reading of $11.8 million, down 73.11% over the prior year.
- Current Deferred Revenue was $9.8 million for Q3 2025 at Tandem Diabetes Care, down from $10.5 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $44.0 million in Q4 2023 and bottomed at $1.1 million in Q1 2024.
- Average Current Deferred Revenue over 5 years is $15.6 million, with a median of $11.0 million recorded in 2025.
- The sharpest move saw Current Deferred Revenue crashed 95.3% in 2024, then soared 897.91% in 2025.
- Year by year, Current Deferred Revenue stood at $10.2 million in 2021, then skyrocketed by 85.0% to $18.8 million in 2022, then soared by 133.55% to $44.0 million in 2023, then tumbled by 73.11% to $11.8 million in 2024, then decreased by 16.79% to $9.8 million in 2025.
- Business Quant data shows Current Deferred Revenue for TNDM at $9.8 million in Q3 2025, $10.5 million in Q2 2025, and $11.0 million in Q1 2025.